Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.36 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.36 |
| ▸ | PCK1 | P35558 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.35 |
| ▸ | CCNB2 | O95067 | 6/20 | 0.34 |
| ▸ | CDK1 | P06493 | 6/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24309875 | 0.90 | HTR1A (0.39) | BRAFBRD4HTR1AHTR7PCK1 | |
| SCHEMBL24309379 | 0.90 | HTR1A (0.39) | BRAFBRD4HTR1AHTR7PCK1 | |
| SCHEMBL24310057 | 0.88 | HTR1A (0.38) | BRAFBRD4HTR1AHTR7PCK1 | |
| SCHEMBL29566809 | 0.88 | HTR1A (0.38) | BRAFBRD4HTR1AHTR7PCK1 | |
| SCHEMBL24309412 | 0.87 | HTR1A (0.36) | BRAFBRD4HTR1AHTR7PCK1 | |
| SCHEMBL24310066 | 0.87 | HTR1A (0.38) | BRAFBRD4HTR1AHTR7PCK1 | |
| SCHEMBL24309608 | 0.86 | HTR1A (0.36) | BRAFBRD4HTR1AHTR7KAT6A | |
| SCHEMBL24309383 | 0.86 | HTR1A (0.39) | HTR1AHTR7KMT2ARXFP1TSHR | |
| SCHEMBL24309547 | 0.86 | HTR1A (0.37) | BRAFBRD4HTR1AHTR7KAT6A | |
| SCHEMBL24309375 | 0.86 | HTR1A (0.37) | BRAFBRD4HTR1AHTR7KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| EP-4225748-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | BRAF 3030/4885BRD4 1716/4885HTR1A 4018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.